OSR Health, Inc. filed a Form S-8 registration statement with the SEC on November 18, 2026, to register 6,300,000 shares of common stock under its 2025 Omnibus Incentive Plan, including a reoffer prospectus covering up to 2,507,256 shares held by directors and executive officers.
Key Highlights
- Total shares registered: 6,300,000 shares of common stock, par value $0.0001 per share, authorized under the 2025 Omnibus Incentive Plan.
- Reoffer prospectus: Up to 2,507,256 shares may be resold by Selling Stockholders who are current directors and executive officers of the company.
- Six-month transfer restriction: All shares covered by the reoffer prospectus are subject to a contractual restriction on transfer and sale for six months following the applicable grant date.
- Nasdaq delisting: On October 24, 2026, a Nasdaq Hearings Panel determined not to grant the company's request for continued listing; trading on Nasdaq has been suspended, and the common stock is currently quoted on the OTC Pink market under the symbol "OSRH."
- Last reported sale price: On November 17, 2026, the last reported sale price of the common stock was $0.10 per share.
- Grant dates: Awards to executive officers and employees (in settlement of unpaid salaries) and to independent directors were originally approved in April and May 2026, with the Board and Compensation Committee resetting the grant date to October 29, 2026.
- Director grants: Independent directors received fully vested stock grants of 120,000 shares per director, granted in full settlement of previously approved equity compensation commitments.
OSR Health S-8 Filing: 2025 Plan Registration and Reoffer Prospectus Details
According to the filing, OSR Health, Inc. (OTC:OSRH) registered 6,300,000 shares of common stock under its 2025 Omnibus Incentive Plan via a Form S-8 registration statement submitted to the SEC on November 18, 2026. The company disclosed that it is a non-accelerated filer, a smaller reporting company, and an emerging growth company incorporated in Delaware with an I.R.S. Employer Identification Number of 84-5052822.
The registration statement includes a reoffer prospectus prepared pursuant to General Instruction C to Form S-8, covering up to 2,507,256 shares that may be offered by Selling Stockholders, described in the filing as the company's current directors and executive officers. The filing states that the company will not receive any proceeds from resales by the Selling Stockholders. Awards to executive officers were granted to settle unpaid salaries and will be issued at a price per share equal to 115% of the volume weighted average price of the common stock for the 15 trading days ended October 28, 2026, the filing disclosed. Independent directors each received fully vested grants of 120,000 shares in settlement of previously approved equity compensation commitments.
The filing also disclosed that all shares under the reoffer prospectus are subject to a six-month contractual transfer restriction, meaning offers and resales pursuant to the reoffer prospectus may not commence until expiration of that restriction period. The filing further noted that the Selling Stockholders "have no present intention to sell any of the shares covered by this prospectus" as of the filing date, and that registration of the shares "should not be taken as an indication that any Selling Stockholder intends to sell, any shares." The company also disclosed that Nasdaq is expected to file a Form 25 notification with the SEC to delist the common stock, and that the shares are currently quoted on the OTC Pink market.
What Was Disclosed
OSR Health filed a Form S-8 on November 18, 2026, registering 6,300,000 shares under its 2025 Omnibus Incentive Plan and including a reoffer prospectus for up to 2,507,256 shares held by directors and executive officers, all subject to a six-month contractual transfer restriction.



Please wait processing your request...